Veröffentlichungen
Im Folgenden finden Sie eine Auswahl wissenschaftlicher Veröffentlichungen rund um die Entdeckungen, auf denen MorphoSys’ Technologien basieren. Die meisten Veröffentlichungen sind nur in englischer Sprache verfügbar.
Englische Zusammenfassungen aus Medline sind verfügbar über ENTREZ durch Öffnen des Links „Abstract“.
Titel | Information | Links |
|---|---|---|
“Efficacy of the fully human monoclonal antibody MOR102 (#5) against intercellular adhesion molecule 1 in the psoriasis-severe combined immunodeficient mouse model” | Boehncke WH, Ochsendorf FR, Noll S, Urban M, Popp A, Waldherr D, Haunschild J, Litzenburger T. Br J Dermatol. 2005 Nov;153(5): 1092 | |
“Monoclonal antibodies from phage display libraries” | Margit Urban Arzneimittel-Forsch (2005) 55 (11): 694-695 | No abstract available |
“Modern Antibody Technology: The Impact on Drug Development” | Simon Moroney and Andreas Plückthun Modern Biopharmaceuticals; Edited by J. Knaeblein, Wiley-VCH Verlag, 2005 ISBN: 3-527-31184-X | No abstract available |
“Protein microarrays for antibody profiling: Specificity and affinity determination on a chip” | Oliver Poetz, Ralf Ostendorp, Bodo Brocks, Jochen M. Schwenk, Dieter Stoll, Thomas O. Joos and Markus F. Templin Proteomics (2005), 5, 2402–2411 | |
“Characterization of high-affinity antibodies by electrochemiluminescence-based equilibrium titration” | Cornelia Haenel, Marion Satzger, Daniela Della Ducata, Ralf Ostendorp and Bodo Brocks Analytical Biochemistry, Volume/Issue 339/1 pp. 182-184, | |
“Antifibrotic effects of a tissue inhibitor of metalloproteinase-1 antibody on established liver fibrosis in rats” | Parsons CJ, Bradford BU, Pan CQ, Cheung E, Schauer M, Knorr A, Krebs B, Kraft S, Zahn S, Brocks B, Feirt N, Mei B, Cho MS, Ramamoorthi R, Roldan G, Ng P, Lum P, Hirth-Dietrich C, Tomkinson A, Brenner DA Hepatology, 2004 Nov;40(5):1106-15 | |
“Generation, engineering and production of human antibodies using HuCAL” | Ralf Ostendorp, Christian Frisch and Margit Urban; ANTIBODIES, Volume 2: Novel technologies and therapeutic use; p.13-52; 2004 Kluwer Academic/Plenum Publishers, New York; ISBN 0-306-48315-7 (v.2) | |
“Human combinatorial Fab library yielding specific and functional antibodies against the human fibroblast growth factor receptor 3” | R. Rauchenberger, E. Borges, E. Thomassen-Wolf, E. Rom, R. Adar, Y. Yaniv, M. Malka, I. Chumakov, S. Kotzer, D. Resnitzky, A. Knappik A, S. Reiffert, J. Prassler, K. Jury, D. Waldherr, S. Bauer, T. Kretzschmar, A. Yayon, C. Rothe J Biol Chem. 2003; Oct 3; 278(40): 38194-38205 | |
“Kirrel2, a novel immunoglobulin superfamily gene expressed primarily in beta cells of the pancreatic islets” | C. Sun, D. Kilburn, A. Lukashin, T. Crowell, H. Gardner, R. Brundiers, B. Diefenbach, J.P. Carulli Genomics 2003; Aug; 82(2): 130-142 | |
“From EST to IHC: human antibody pipeline for target research” | C. Frisch, B. Brocks, R. Ostendorp, A. Hoess, T. von Rüden and T. Kretzschmar J Immunol Methods 2003; Apr 1; 275(1-2): 203-212 | |
“Antibody discovery: phage display” | T. Kretzschmar, T. von Rüden Curr Opin Biotechnol. 2002; Dec, 13(6):598-602 | |
“Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells” | Nagy ZA, Hubner B, Lohning C, Rauchenberger R, Reiffert S, Thomassen-Wolf E, Zahn S, Leyer S, Schier EM, Zahradnik A, Brunner C, Lobenwein K, Rattel B, Stanglmaier M, Hallek M, Wing M, Anderson S, Dunn M, Kretzschmar T, Tesar M. Nature Medicine 2002; Aug; 8(8): 801-807 | |
“High-throughput generation and engineering of recombinant human antibodies” | Krebs B, Rauchenberger R, Reiffert S, Rothe C, Tesar M, Thomassen E, Cao M, Dreier T, Fischer D, Hoss A, Inge L, Knappik A, Marget M, Pack P, Meng XQ, Schier R, Sohlemann P, Winter J, Wolle J, Kretzschmar T. J Immunol Methods. 2001; Aug 1; 254(1-2) | |
“Titration of Infective and Noninfective Ff Filamentous Bacteriophages Using a Monoclonal Antibody against g3p” | C. Frisch, A. Knappik, M. Choidas, M. Tesar BioTechniques 2000; Jul; 29 (1): 26-28 | |
“Bypassing hybridoma technology: HLA-C reactive human single-chain antibody fragments (scFv) derived from a synthetic phage display library (HuCAL®) and their potential to discriminate HLA class I specificities” | M. Marget, B.B. Sharma, M. Tesar, T. Kretzschmar, S. Jenisch, E. Westphal, P. Davarnia, E. Weiss, M. Ulbrecht, D. Kabelitz, M. Krönke Tissue Antigens 2000; 56: 1-9 | |
“Fully Synthetic Human Combinatorial Antibody Libraries (HuCAL®) Based on Modular Consensus Frameworks and CDRs Randomized with Trinucleotides” | (Copyright 2000 by Academic Press) A. Knappik, L. Ge, A. Honegger, P. Pack, M. Fischer, G. Wellnhofer, A. Hoess, J. Wölle, A. Plückthun, B. Virnekäs J Mol Biol. 2000 Feb 11; 296 (1): 57-86. | |
“New protein engineering approaches to multivalent and bispecific antibody fragments” | A. Plückthun, P. Pack Immunotechnology. 1997 Jun; 3(2): 83-105 | |
“Setting up a Biotechnology Business in Germany” | S.E. Moroney Journal of Biotechnology in Healthcare. 1997 April 7; 4(1): 67-75. | |
“Multivalent antibody fragments with high functional affinity for a tumor-associated carbohydrate antigen” | M. Rheinnecker, C. Hardt, L.L. Ilag, P. Kufer, R. Gruber, A. Hoess, A. Lupas, C. Rottenberger, A. Plückthun, P. Pack The Journal of Immunology. 1996 Oct 1; 157(7): 2989-2997. | |
“Trinucleotide phosphoramidites: ideal reagents for the synthesis of mixed oligonucleotides for random mutagenesis” | B. Virnekäs, L. Ge, A. Plückthun, K.C. Schneider, G. Wellnhofer, S.E. Moroney Nucleic Acids Research. 1994 Dec 25; 22(25): 5600-5607. | |
“Improved bivalent miniantibodies, with identical avidity as whole antibodies, produced by high cell density fermentation of Eschericia coli” | P. Pack, M. Kujau, V. Schroeckh, U. Knupfer, R. Wenderoth, D. Riesenberg, A. Plückthun BIO/TECHNOLOGY. 1993 Nov; 11(11): 1271-1277 |